SCHEMBL2201625

SCHEMBL2201625

Cn1nc(-c2ccccc2-c2cc3ccccc3o2)cc1C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.58
ALDH1A1 P00352 6/20 0.58
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
MAPT P10636 4/20 0.42
HSD17B10 Q99714 2/20 0.42
HPGD P15428 1/20 0.42
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
F2RL3 Q96RI0 3/20 0.41
POLB P06746 1/20 0.41
TSHR P16473 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2202749 0.87 CA12 (0.49) KDM4EALDH1A1CA12CA1CA2
SCHEMBL2201623 0.83 KDM4E (0.56) KDM4EALDH1A1CA12CA1CA2
SCHEMBL2199129 0.78 KDM4E (0.46) KDM4EALDH1A1CA12CA1CA9
SCHEMBL3643053 0.77 HTR2A (0.50) KDM4EALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL2199010 0.76 KDM4E (0.45) KDM4EALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL2199993 0.75 HTR2A (0.51) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL3436593 0.74 CA12 (0.55) KDM4EALDH1A1CA12CA1CA2
SCHEMBL2230937 0.73 HTR2A (0.43) KDM4EALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL2202745 0.71 KDM4E (0.45) KDM4EALDH1A1CA12CA1CA2
SCHEMBL2209825 0.71 TSHR (0.58) KDM4EALDH1A1CA12CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
EP-2182953-A2 NEW PYRAZOL DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-05-12 EP disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 KDM4E 3694/4885ALDH1A1 1476/4885CA12 3274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.